Autres langues Lipocine Inc.

Actions

LPCN

US53630X2036

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
4,68 ^USD	-0,43%		-2,45%	+67,74%

01/05	Lipocine annonce la fin du dosage dans l'étude pivot du candidat à la dépression du post-partum, le LPCN 1154	CI
12/04	Lipocine annonce que le LPCN 2401 montre une amélioration de la composition corporelle dans un essai de phase intermédiaire	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	01/05
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154	01/05
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	12/04
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	12/04
Top Premarket Gainers	11/04
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	11/04
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	28/03
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	28/03
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug	25/03
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	25/03
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	25/03
Lipocine : Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - Form 8-K	25/03
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023	08/03
Lipocine : Announces Financial Results for the Full Year Ended December 31, 2023 - Form 8-K	07/03
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Lipocine to Present at 36th Annual Roth Conference	06/03
Lipocine : to Present at 36th Annual Roth Conference - Form 8-K	06/03
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	06/02
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	06/02
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals	02/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lipocine Inc.

Actions

LPCN

US53630X2036

Autres langues

Filtres